Neurogene Inc (NGNE) Stock Price, Quote & News

Company Profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LL...

Industry: Biotechnology

Sector: Healthcare

Phone: 855 508 3568

Website: www.neurogene.com

Address:

535 W 24th Street, 5th Floor, New York, United States

Quantumup Nov. 14 at 12:45 PM

Cantor reit $TSHA OW13 $NGNE $ACAD Neurogene (NGNE, NC) reported updated Phase 1/2 data for its ICV-administered gene therapy NGN-401 in Rett syndrome (rare neurodevelopmental disorder). From our conversations, we believe investors have spent more time focusing on key differences between the approaches, although there have also been questions about how to interpret cross-data comparisons with Taysha's TSHA-102 (intrathecally administered AAV9-based gene therapy). NGNE shares closed -15% today (vs. -8% for TSHA), which we believe could be in part related to some of the treatment-related AEs that were disclosed in NGNE's release. While we believe both companies are assessing natural history datasets to understand what is deemed a milestone, skill, etc., we don't fully appreciate or understand what analysis NGNE evaluated their data against. Nor do we fully understand the statistical analysis plan NGNE has put into place to fully appreciate what is deemed a "responder" in their pivotal trial.

0 · Reply

d_risk Nov. 13 at 10:03 PM

$NGNE - Neurogene Inc. Common Stock - 10Q - Updated Risk Factors NGNE’s risk factors now spotlight its heavy reliance on NGN-401’s clinical success, major funding needs, manufacturing and supply chain hurdles, regulatory and commercialization uncertainties, new exposure to tariffs and cyberattacks, and the removal of litigation and public company compliance disclosures. #Biotechnology #Tariffs #Cybersecurity #RegulatoryUncertainty #SupplyChain #FundingRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NGNE/10-Q/2025-11-13

0 · Reply

Houseofsweeps Nov. 13 at 3:03 PM

$NGNE $TSHA jumped 70% from good results. Ngne had less patients achieve more milestones and it’s down 8% today 🤣😅

0 · Reply

JarvisFlow Nov. 13 at 12:44 PM

HC Wainwright & Co. has updated their rating for Neurogene ( $NGNE ) to Buy with a price target of 70.

0 · Reply

Thestocktraderhubzee Nov. 13 at 11:37 AM

WATCHLIST NOV 13 2025 $IMTX Immatics shares are trading higher after the company announced updated Phase 1a dose escalation data from both product candidates in its TCR Bispecifics pipeline $NGNE Neurogene Announces Updated Interim Clinical Study In Pediatric Group From Its Current Phase 1/2 Trial Evaluating NGN-401 Demonstrates All 8 Patients Showed Functional Gains Across Spectrum Of Disease Severity $JOBY Joby And General Authority Of Civil Aviation Of The Kingdom Of Saudi Arabia Announce Plans For Rapid Deployment Of Joby's electric Air Taxi In The Kingdom $ONON http://Alarm.com Launches Smart ADC-V730 Camera Combining 4MP Video, Color Night Vision, And Real-Time AI Threat Response $ALRM http://Alarm.com Launches Smart ADC-V730 Camera Combining 4MP Video, Color Night Vision, And Real-Time AI Threat Response

0 · Reply

Ho_loop Nov. 11 at 8:42 PM

$NGNE NXXT chart = deception. Tape dead, but funds are hunting. Geode went full throttle. Vanguard, UBS, BlackRock — all added big. 48 total. Entry now or chase later. Earnings window is cracked open. 💥

0 · Reply

Joe_Mama Nov. 11 at 8:14 PM

$NGNE Let’s climb up the right side

1 · Reply

Joe_Mama Nov. 11 at 8:10 PM

$NGNE Me likie!

0 · Reply

calibubbles Nov. 5 at 8:13 PM

$NGNE 45 by fri

0 · Reply

Dark_Horse_Investments Nov. 3 at 5:20 PM

$TSHA What is happening to our gem, down ~10? Even the skull drilling competitor, $NGNE, better suited to market its drilling services to Elon’s BORE company, is also down, bigger ~17%. $XBI is also down ~3%. Is this related to FDA, fresh concerns with gene therapies, overall biotech selloff? Kindly share any thoughts or finding… An opportunity to add TSHA!

1 · Reply

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Nov 12, 2025, 7:51 PM EST - 1 day ago

Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 12, 2025, 4:01 PM EST - 2 days ago

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Nov 6, 2025, 7:30 AM EST - 8 days ago

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Nov 5, 2025, 4:01 PM EST - 9 days ago

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2025, 7:00 AM EDT - 5 weeks ago

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

Oct 8, 2025, 7:30 AM EDT - 5 weeks ago

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 3, 2025, 4:01 PM EDT - 6 weeks ago

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 11, 2025, 4:10 PM EDT - 3 months ago

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NTLA QURE RCKT

Jun 30, 2025, 4:01 PM EDT - 4 months ago

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

May 16, 2025, 7:00 AM EDT - 6 months ago

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 9, 2025, 7:30 AM EDT - 6 months ago

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

Apr 28, 2025, 5:00 PM EDT - 7 months ago

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Apr 2, 2025, 4:01 PM EDT - 8 months ago

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Mar 24, 2025, 4:10 PM EDT - 8 months ago

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Feb 24, 2025, 7:30 AM EST - 9 months ago

Neurogene to Participate in Upcoming Conferences

Nov 28, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out

Nov 27, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation

Nov 26, 2024, 10:00 AM EST - 1 year ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Nov 25, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation

Nov 24, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect

Nov 22, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation

Nov 20, 2024, 10:00 AM EST - 1 year ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 18, 2024, 5:25 PM EST - 1 year ago

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Nov 18, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect

Nov 18, 2024, 6:45 AM EST - 1 year ago

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 17, 2024, 10:00 AM EST - 1 year ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 15, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation

Nov 14, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation

Nov 13, 2024, 11:30 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out

Nov 12, 2024, 11:25 AM EST - 1 year ago

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Nov 11, 2024, 4:01 PM EST - 1 year ago

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 4, 2024, 7:30 AM EST - 1 year ago

Neurogene Announces Oversubscribed $200 Million Private Placement

Oct 21, 2024, 7:30 AM EDT - 1 year ago

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Aug 7, 2024, 7:30 AM EDT - 1 year ago

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Neurogene to Participate in BMO Genetic Medicines Summit

Jul 1, 2024, 7:30 AM EDT - 1 year ago

Neurogene Announces Addition to Russell 3000® Index

Jun 18, 2024, 9:26 AM EDT - 1 year ago

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Quantumup Nov. 14 at 12:45 PM

0 · Reply

d_risk Nov. 13 at 10:03 PM

0 · Reply

Houseofsweeps Nov. 13 at 3:03 PM

$NGNE $TSHA jumped 70% from good results. Ngne had less patients achieve more milestones and it’s down 8% today 🤣😅

0 · Reply

JarvisFlow Nov. 13 at 12:44 PM

HC Wainwright & Co. has updated their rating for Neurogene ( $NGNE ) to Buy with a price target of 70.

0 · Reply

Thestocktraderhubzee Nov. 13 at 11:37 AM

0 · Reply

Ho_loop Nov. 11 at 8:42 PM

0 · Reply

Joe_Mama Nov. 11 at 8:14 PM

$NGNE Let’s climb up the right side

1 · Reply

Joe_Mama Nov. 11 at 8:10 PM

$NGNE Me likie!

0 · Reply

calibubbles Nov. 5 at 8:13 PM

$NGNE 45 by fri

0 · Reply

Dark_Horse_Investments Nov. 3 at 5:20 PM

1 · Reply

kshonstocks Oct. 27 at 3:43 PM

$NGNE nice 9 dma recovery pattern

0 · Reply

stockanalysis_ Oct. 21 at 10:08 PM

Stocks with short float > 50% $CAR $ZBIO $AIRS $NGNE $FLWS Replicate this screener here: https://stockanalysis.com/stocks/screener/?ref=saveontrading

0 · Reply

Quantumup Oct. 20 at 8:30 PM

Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:

0 · Reply

Dark_Horse_Investments Oct. 17 at 9:49 PM

seems $NGNE was more dependent on the Astellas exclusive rights to acquire RETT asset (company) from $TSHA than tsha was to hold price level As astellas exclusivity expired on ~ 09/30/25, as confirmed yesterday by TSHA sec filing, both companies traded down today (logically TSHA was expected to face trading pressure) notwithstanding TSHA down -7% NGNE down -14.5% where is the fluff valuation ?

0 · Reply

JFais Oct. 17 at 2:23 PM

Gene therapy players in Rett $NGNE $TSHA at top of losers scan today

0 · Reply

Grouphome Oct. 14 at 6:54 PM

$NGNE nice

2 · Reply

Guptasulo Oct. 13 at 5:32 PM

$TSHA $NGNE Here is a detailed comparison between TSHA and NGNE Administration route -Simpler, scalable IT delivery Gene regulation-miRARE self-regulation prevents overexpression unlike NGNE Clinical maturity -6-month efficacy, FDA BLA path defined Safety margin- Clean to date; self-limiting expression Regulatory support- RMAT, Fast Track, Orphan; BLA-ready Manufacturing partner ready - Astellas commercialization Capital position - Fully funded through pivotal stage Competitive risk - 12–18 month lead over NGNE

1 · Reply

Quantumup Oct. 13 at 3:36 PM

Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. $NGNE $ACAD $ALPMY Citizens JMP added: A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett gene therapy competitor. We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: Overall, both TSHA & NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. Based on the more involved procedure required for ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.

0 · Reply

Quantumup Oct. 9 at 4:18 PM

BofA⬆️ $TSHA's PT to $9 from $8 and reiterated at a Buy. BofA currently assigns TSHA-102 a 60% LoS & 40% mkt shr for peak risk-adj'd sales of $1.3B in '31 ('27 launch), whereas its KOLs think the geneTx could capture 80% of mkt. $ACAD $NGNE Here's what BofA had to say:

0 · Reply

MaverikIT Oct. 9 at 1:41 PM

$NGNE - nice week

0 · Reply

Doozio Oct. 9 at 1:29 AM

$NGNE yo 🐑 boi! They all been SPOT. Slap a 🐒🍌 on that 🧠⏰♾️

0 · Reply

StockScanners Oct. 4 at 3:43 PM

$NGNE reached 24.50

0 · Reply

Market Cap	443.57M
Revenue (ttm)	930,000.00
Net Income (ttm)	-75.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8,079.57%
Debt to Equity Ratio	0.00

Volume	339,019
Avg Vol	236,476
Day's Range	N/A - N/A
Shares Out	14.27M
Stochastic %K	28%
Beta	1.64
Analysts	Strong Sell
Price Target	$51.40